Research & KnowledgeEvent: September 3, 2026
Cavidi published an in-depth explainer explaining how BOLD technology makes immunoassays 10–100x more sensitive.
Published
Signal category
Research & Knowledge
Quote
“Here’s an in-depth explainer.”
— Cavidi team
Company
Cavidi
Enabling ultra-sensitive immunoassays
- Industry
- Biotechnology Research
- Location
- Uppsala, SE
- Company size
- 20 employees
Cavidi is a Swedish biotech firm that is transforming the field of biomarker detection with our groundbreaking solution, Exazym® — the world’s first add-on reagent system that delivers ultra-sensitive detection of low-abundance biomarkers using standard immunoassay workflows. Cavidi's products are used globally by biomedical scientists and researchers working on basic, transitional and pre-clinical biomarker research.
Founded 1984